Kruklar

Clarithromycin, the active ingredient in Kruklar, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats bacterial infections such as community‑acquired pneumonia, sinusitis, skin infections, Helicobacter pylori infection and streptococcal pharyngitis in adults and children as prescribed. GNH USA supplies Kruklar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is employed to treat bacterial infections across several organ systems. - Community‑acquired pneumonia: eradicates the causative bacteria and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Skin and soft tissue infections: eliminates pathogenic bacteria and promotes wound healing. - Helicobacter pylori infection: part of combination therapy to achieve bacterial eradication. - Streptococcal pharyngitis: resolves throat infection and prevents complications.

Clarithromycin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: transient headache episodes. - Vomiting: occasional emesis.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT prolongation: cardiac rhythm disturbance that can lead to arrhythmia. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Clostridioides difficile‑associated diarrhea: severe colitis. - Stevens‑Johnson syndrome: life‑threatening skin reaction. - Cardiac arrhythmias: irregular heartbeats beyond QT issues.

Clarithromycin requires careful consideration of patient‑specific factors before use. - Pregnancy: Category C; use only if potential benefits justify the risk. - Renal impairment: dose adjustment may be necessary in severe dysfunction. - Hepatic impairment: monitor liver function tests during therapy. - Drug interactions: review concomitant medications for potential QT‑prolonging agents. - QT prolongation risk: avoid in patients with known prolonged QT interval. - Store at room temperature: keep in the original container, protect from moisture.

Clarithromycin can alter the plasma levels of several co‑administered drugs.

Major Interactions (Avoid): - Erythromycin and other macrolides: additive QT‑prolongation risk. - Cisapride: may cause serious cardiac events. - Pimozide: increased plasma concentrations leading to toxicity. - Terfenadine: heightened risk of arrhythmia. - St. John’s wort: reduces clarithromycin exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - Theophylline: elevated levels can cause toxicity. - Carbamazepine: may decrease clarithromycin efficacy. - Statins (e.g., lovastatin): increased risk of myopathy.